A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study

被引:3
|
作者
Sheehan, Rory [1 ]
Strydom, Andre [2 ]
Marston, Louise [3 ]
Morant, Nicola [1 ]
Fiori, Federico [4 ]
Santosh, Paramala [5 ]
Hassiotis, Angela [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England
[3] UCL, Res Dept Primary Care & Populat Hlth, London, England
[4] Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, London, England
[5] Kings Coll London, Dept Child & Adolescent Psychiat, London, England
来源
BMJ OPEN | 2019年 / 9卷 / 12期
基金
美国国家卫生研究院;
关键词
CHALLENGING BEHAVIOR; PEOPLE; PREVALENCE; MANAGEMENT; PATIENT; IMPACT;
D O I
10.1136/bmjopen-2019-033827
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To investigate the feasibility of delivering structured psychotropic medication review in community services for adults with intellectual disability (ID). Design Single-arm feasibility study conducted over a 6-month period. Setting Specialist community ID teams in England. Participants Psychiatrists working with adults with ID and adults with ID who had been prescribed psychotropic medication. Intervention A structured web-based psychotropic medication review tool (the HealthTracker-based structured medication review) comprising measures of therapeutic benefit and adverse side-effects was made available for use by psychiatrists in routine clinic appointments. A summary measure of medication effectiveness was graphically presented to aid discussion and decision-making. Main outcome measures Feasibility metrics including number of people with ID referred, eligible and recruited, and uptake of the medication review tool in naturalistic clinical settings. Psychiatrist and patient feedback was collected to assess acceptability of the intervention and suggestions for development. Results Fifteen psychiatrists from five clinical teams took part. In total 94 potentially eligible people with ID were referred, of whom 79 (84%) were recruited and together underwent 97 medication reviews over the 6-month study period. Feedback from participants with ID was favourable. Psychiatrists indicated that the HealthTracker-based structured medication review was broadly acceptable and suggested adaptations to improve integration with existing information technology systems and to enhance patient involvement in the review. Conclusions Structured psychotropic medication review can be used in community services for adults with ID as part of a programme of medication optimisation. It would be feasible to test clinical and patient outcomes of the HealthTracker-based medication review in a randomised clinical trial.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] PREVALENCE OF PSYCHOTROPIC MEDICATION TREATMENT IN ADULTS WITH INTELLECTUAL DISABILITIES IN GERMANY
    Dobrindt, J.
    Koch, A.
    Schuetzwohl, M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 696 - 696
  • [22] Medication load and frailty in older adults with intellectual disability: An observational study
    O'Connell, Juliette
    Henman, Martin Charles
    McMahon, Niamh
    Burke, Eilish
    McCallion, Philip
    McCarron, Mary
    O'Dwyer, Maire
    JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2021, 34 (05) : 1307 - 1307
  • [23] Factors Associated with the Use of Psychotropic Medication in a Norwegian Community-Based Sample of Adults with Intellectual Disability
    Pedersen, Erlend Refseth
    Anke, Audny
    Tessem, Silje Marie
    Olsen, Monica Isabel
    Sondenaa, Erik
    JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES, 2025,
  • [24] Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia
    Song, Menghuan
    Ware, Robert S.
    Doan, Tan N.
    McPherson, Lyn
    Trollor, Julian N.
    Harley, David
    BJPSYCH OPEN, 2020, 6 (06):
  • [25] Longitudinal psychotropic medication patterns among former residents with intellectual disability in Ontario
    Hansford, Rebecca
    Condillac, Rosemary
    JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2021, 34 (05) : 1318 - 1318
  • [26] Prevalence and patterns of psychotropic medication treatment in adults with intellectual disabilities in germany
    Schuetzwohl, M.
    Koch, A.
    Dobrindt, J.
    EUROPEAN PSYCHIATRY, 2020, 63 : S410 - S411
  • [27] Medication management in intellectual disability settings: A systematic review
    Sheerin, Fintan
    Wuytack, Francesca
    Eustace-Cook, Jessica
    Doyle, Carmel
    JOURNAL OF INTELLECTUAL DISABILITIES, 2021, 25 (02) : 242 - 276
  • [29] Developing a Medication Review Tool to Assess Medication Use in Cognitive Impairment and Dementia: A Feasibility Study
    Abu Fadaleh, S.
    Ivo, J.
    Faisal, S.
    Carducci, J.
    Lee, L.
    Sadowski, C. A.
    Chang, F.
    Patel, T.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S29 - S29
  • [30] Psychotropic medication for problem behaviours in intellectual disability and autism spectrum disorder: the need for caution
    Bertelli, Marco O.
    BJPSYCH ADVANCES, 2023, : 334 - 336